

Low-dose and off-label use of antipsychotics: current evidence and clinical considerations
Since the discovery of chlorpromazine in the 1950s, antipsychotics have been a cornerstone in the treatment of schizophrenia and paranoid psychosis. Beyond psychotic conditions, several antipsychotics are also approved for affective disorders (e.g., flupentixol or quetiapine for depression; aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone for treatment and prevention of mania), for delirium (haloperidol), and for persistent aggression associated with dementia


